AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Use of Pyroglutamyl-Glutamyl-Prolyl Amide (Eep) for Neurological and Neurobehavioral Disorders

Detailed Technology Description
None
Supplementary Information
Patent Number: US6475989B1
Application Number: US1998169657A
Inventor: Sattin, Albert | Pekary, Albert E. | Lloyd, Robert L.
Priority Date: 9 Oct 1997
Priority Number: US6475989B1
Application Date: 9 Oct 1998
Publication Date: 5 Nov 2002
IPC Current: A61K003806 | C07K0005097 | A61K003800
US Class: 5140175 | 514018 | 530331
Title: Use of pyroglutamyl-glutamyl-prolyl amide (EEP) for neurological and neurobehavioral disorders
Usefulness: Use of pyroglutamyl-glutamyl-prolyl amide (EEP) for neurological and neurobehavioral disorders
Summary: For the treatment of depression, schizophrenia and affective disorders (claimed) e.g. anxiety and mood disorders. Also useful for the treatment of neuromuscular weakness, spinal cord trauma, spasticity, dementia, Alzheimer's disease, somatization disorders, psychosomatic disorders, functional bowel disorders, epileptic disorders, sleep disorders and loss of motoric or cognitive functions resulting from spinal cord or brain stem injuries.
Novelty: Treatment of neurological and neurobehavioral disorders e.g. depression involves use of a composition comprising a tri-peptide or its salt
Industry
Disease Diagnostic/Treatment
Sub Category
Other Disease
Application No.
6475989
Others

Tech ID/UC Case

22315/2009-717-0


Related Cases

2009-717-0

*Abstract
A tri-peptide drug for treatment of neurological and neurobehavioral disorders of a mammal, such drug being derived from the following formula: pGlu-X-Pro-NH 2 , wherein the internal amino acid (X) is a non-histadine amino acid. Methods of treatment of neurological disorders using the tri-peptide, including as an adjunct, synergist or stand-alone therapy, in oral, parenteral, intranasal, transcutaneous, or rectal forms.
*IP Issue Date
Nov 5, 2002
*Principal Investigator

Name: Robert Lloyd

Department:


Name: Albert Pekary

Department:


Name: Albert Pekary

Department:


Name: Albert Sattin

Department:


Name: Albert Sattin

Department:

Country/Region
USA

For more information, please click Here
Mobile Device